Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Vomiting 5Nausea 4Testicular Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy 1Radiation Injuries 1Neoplasms 1Lung Neoplasms 1

Interventions

Etoposide 4Cisplatin 4Ifosfamide 3Filgrastim 3Carboplatin 3Bleomycin 3pegfilgrastim 2Paclitaxel 2lerisetron 1isophosphamide mustard 1Watchful Waiting 1Vinblastine 1Surveys and Questionnaires 1Sorafenib 1Radiotherapy 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Olanzapine 1Magnetic Resonance Spectroscopy 1Lenograstim 1Granisetron 1Gemcitabine 1Flow Cytometry 1Drug Therapy 1Dexamethasone 1Chemotherapy, Adjuvant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Testicular Neoplasms × Olanzapine × Clear all
NCT05244577 2023-02-06

Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer

Sun Yat-sen University

Phase 3 Unknown
75 enrolled
Genitourinary

Nausea, Testicular Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡